Please provide your email address to receive an email when new articles are posted on . Patients with pemphigus treated with rituximab had a longer disease-free survival than those treated with ...

Please provide your email address to receive an email when new articles are posted on . Rituximab is associated with higher protection against long-term cardiovascular and metabolic diseases, but ...

LONDON — The Belgian company Argenx said Wednesday that its closely watched antibody therapy failed to outperform placebo in a Phase 3 trial in an autoimmune condition that causes the skin to blister ...

The acronym PEMPHIGUS is suggested to encompass the numerous factors involved in the pathogenesis and course of the disease. In the following review the authors present studies documenting these ...

Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line ...

Pemphigus vulgaris (PV) is a life-threatening autoimmune disease affecting the skin, causing painful erosions on the skin and ...

Pemphigus is a rare autoimmune blistering disease involving the skin and mucous epithelia. It is clinically characterized by flaccid blisters and erosions (Figure 1) and, if left untreated, could be ...

Shares of argenx plummeted after lead asset Vyvgart (efgartigimod) failed to meet endpoints in a phase 3 trial for the treatment of pemphigus vulgaris and pemphigus foliaceus. The failure also has ...

Argenx SE CEO Tim Van Hauwermeiren said that, with subcutaneous efgartigimod (efgartigimod alfa and hyaluronidase-qvfc) in pemphigus, the company is “facing a situation where, even with a strong ...

Shares of argenx SE ARGX were down 25.1% on Dec 20 after the company announced top-line data from the phase III ADDRESS study, which evaluated efgartigimod subcutaneous (SC) (efgartigimod alfa and ...